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National Institutes of Health; Department of Health and Human Services; National Cancer Institute, Grant/Award Number: HHSN261201500005C Summary Background: Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia.
Aim: To assess utility of these markers in a Western population.
Methods: SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. We used Cox proportional hazards models adjusted for potential confounders to estimate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI) for low SPG1 (<25 lg/L). In a subset (n = 3555) with anti-H. pylori serology, these markers jointly Results: There were 329 gastric cancers diagnosed an average of 13.9 years after baseline. Pre-diagnostic low SPG1 was significantly associated with increased gastric cancer risk (HR 2.68, 95% CI 1.99-3.61). Among subjects with both SPG1 and H. pylori serology, groups B, C and D had increased gastric cancer ORs (95% CI) of 1.79 (1.21-2.64), 3.85 (2.36-6.28) and 6.35 (2.20-18.34) , respectively. CagA seropositives had significantly higher ORs than CagA seronegatives within group B (P heterogeneity = 0.01). For groups B and C, repeat SPG1 level at 3 years did not further stratify gastric cancer risk.
Conclusions: Low SPG1 was associated with increased gastric cancer risk in our large Finnish cohort. A single measurement of SPG1 along with H. pylori whole cell and CagA serology provides potentially useful prediction of gastric cancer risk.
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| INTRODUCTION
Chronic infection with Helicobacter pylori (H. pylori) is well-known to be a strong risk factor for gastric cancer. [1] [2] [3] H. pylori colonization of the gastric mucosa induces inflammation that causes chronic gastritis and mucosal atrophy that may eventually lead to gastric cancer. 4, 5 Serological response to infection by H. pylori can be assessed by measuring anti-H. pylori immunoglobulin G (IgG) antibodies using assays based on whole cell sonicate or one or more individual bacterial antigens. 6 Altered levels of serum pepsinogens (SPG), which are mainly produced by the chief cells of the fundic glands of the stomach, reflect the atrophic status (ie, gland loss) of gastric mucosa. Thus, the combination of the two markers has been suggested to overcome the limits of each, and this has been applied in Japan as a screening tool for gastric cancer, an approach known as the "ABC(D)
method." 21, 23 A recent meta-analysis of East Asian studies reported a gastric cancer meta-HR as high as 13 times in the highest risk group. 24 Previous studies in Western populations that examined the joint association of serum pepsinogen and anti-H. pylori seropositivity with gastric cancer risk have been limited in sample size (less than 100 cases), 11, 13, 25 did not provide overall risk estimates for the combined effects, [26] [27] [28] and/or were not adjusted for possible confounders. 12 Gastric cancer is a heterogenous disease, with important epidemiological differences in among subtypes. For instance, with regards to anatomical subsites, H. pylori is a major risk factor for noncardia but not for cardia gastric cancer. 29 Divergent incidence trends have been reported for these subtypes in different populations. 30, 31 While intestinal-type gastric cancer is often related to environmental factors such as H. pylori or diet, diffuse-type cancer is more closely associated with genetic predisposition. 32 Furthermore, some studies report stronger associations with higher anti-H. pylori antibody titre and/or infection with cytotoxin-associated gene A (CagA) virulence factor-positive strains. 33, 34 The high mortality rate of gastric cancer is mostly a consequence of late detection, stemming from the lack of specific symptoms of the disease. 35, 36 Gastric cancer when found early may be curable by endoscopic or minimally invasive surgery. 37 In countries of high gastric incidence where general population screening by endoscopy is not routinely conducted, triaging high risk individuals for definitive evaluation by endoscopy would be useful. However, the utility of non-invasive risk stratification by blood tests has not been evaluated outside of a few high-income Asian countries. Therefore, the aims of this study are to evaluate the association of low serum pepsinogen 1 
| Identification and classification of cancer cases
The intervention phase ended in April, 1993, but subjects have been passively followed up using the Finnish Cancer Registry which has nearly 100% case coverage of the ATBC cohort. 49 Diagnoses of gas- | 495 types, were separately assessed. 50 The median time to gastric cancer diagnosis was 13.9 (Standard Deviation, SD, 6.8) years.
| Laboratory analysis
SPG1 analyses were performed by radioimmunoassay in two laboratories. Serum samples were assayed at the laboratory of I. M. Samloff, Sepulveda, California, USA during 1989-1991. 51 After that facility was damaged by an earthquake, the remaining samples were assayed at the laboratory of M. H€ ark€ onen, Helsinki, Finland from 1992 to 1993. 14, 15 The SPG1 measurements from the two laboratories were standardized and transformed for compatibility, with low SPG1 defined as 25 lg/L or less, as previously reported. Antibody titre and anti-CagA seropositivity were evaluated for further refinement of anti-H. pylori associations with gastric cancer risk.
| Statistical analyses
Gastric cancer hazard ratios (HRs) and 95% confidence intervals (95% CI) associated with low SPG1 were estimated using Cox proportional hazards models. For each participant, follow-up time was calculated from the date of randomization until the diagnosis of cancer, death or T A B L E 1 Baseline characteristics for ATBC study participants who did or did not develop gastric cancer in the overall study cohort and in the subgroup with both H. pylori serology and serum pepsinogen 1 measurements 57 The associations with histologic subtypes were assessed in both the Cox proportional hazards model and in the logistic models.
The effects of changes between baseline and 3-year follow-up SPG1 within each ABCD group were analysed using logistic regression. The 3-year follow-up measurements were available for 3462 subjects, approximately 97.4% of the participants with both baseline SPG1 and H. pylori serology information. Lag analyses were conducted to estimate marker associations with incident gastric cancer occurring less than 5 years, 5-10 years and more than 10 years after enrolment.
Sensitivity analyses were performed by: 1) excluding overlapping and unspecified subsites for noncardia cancer, 2) limiting to only cancerfree controls and 3) using a previously defined gastric cancer nested case--control set. 45 To address the concern for potential bias in case ascertainment due to pepsinogen measurement, two sensitivity analyses were performed. First, a log-rank test assessed whether gastric Inc, Cary, NC). All P values were two-sided, and were considered significant for P < .05.
| RESULTS
The baseline characteristics of the total cohort and gastric cancer cases, and subjects with both H. pylori serology and pepsinogen (P heterogeneity = 0.01). There was no significant difference by CagA status in group C (P heterogeneity = 0.06).
The trend across groups was statistically significant in intestinaltype gastric cancer (P trend <0.0001) but not in diffuse-type gastric cancer in multivariate analysis (P trend = 0.25) ( Table 5 ).
Gastric cancer risks associated with 3-year change in SPG1 are shown in Figure 1 . Within group B high titre vs low titre H. pylori (P heterogeneity = .23), group C high titre vs low titre H. pylori (P heterogeneity = .52) in model 2.
c Within group B CagA (+) vs CagA (À) (P heterogeneity = .01), group C CagA (+) vs CagA (À) (P heterogeneity = .06) in model 2.
Similarly, in the combined analysis of SPG1 and anti-H. pylori seropositivity, group D, which is mainly the association of low SPG1 Three separate sensitivity analyses restricting the noncardia cases excluding overlapping and unspecified site (Table S2 ), using only noncancer controls from subset of the cohort with both SPG1
and H. pylori serology information available from previous nested case-control sets ( Figure S2 ), and testing within one nested casecontrol set for gastric cancer risk ( Figure S3 ) did not change the risk estimates or the trend of risk.
Based on the log-rank test, there was no significant difference in gastric cancer incidence between those with SPG1 testing and those without (P = .38). Furthermore, the fraction of early gastric cancer did not differ between these two groups (P = .19).
| DISCUSSION
We report the largest study of the association of SPG1 and H. pylori serology with gastric cancer risk in a Western population. Our analyses were based on combined marker categories similar to the Japanese "ABC(D)" method which defines low pepsinogen as PGI ≤ 70 ng/mL and PGI/PG II ≤ 3.
Despite the difference in definition of low pepsinogen, the risk estimates for noncardia gastric cancer derived from our study are similar to estimates for overall gastric cancer from previous studies in Asia, where cardia cancer is relatively uncommon [58] [59] [60] [61] [62] (Table S3 ).
There are only limited studies that further stratify H. pylori seropositivity within ABCD groups in relation to gastric cancer risk.
In our study, titre of anti-H. pylori antibodies was not associated with level of risk among participants with normal SPG1 status (ie, group B). Among individuals with low SPG1 status (ie, group C), the nonsignificantly higher OR we found for low anti-H. pylori antibody titre may reflect longer exposure to H. pylori infection and more severe disease progression leading to diminished antibody production. 63 Previous reports in Asian populations have been inconsistent, associating increased gastric cancer risk with high antibody titre in some studies 59, 64 and with low titre in others. 33, 65 To the best of our Another point to note is the assessment of the usefulness of repeated measurement of SPG1 in predicting gastric cancer risk (Figure 1 ). Our analysis shows that a 3-year follow-up of SPG1 does not differentiate risk within baseline categories of B and C. The current analysis cannot provide evidence for other follow-up intervals but, in our lag analysis for prediagnostic SPG1, the association of SPG1
with gastric cancer was highest in the first five years prior to diagnosis (Table S1 ). Therefore, we cautiously conclude that repeated measurement may not be necessary for SPG1 and H. pylori serology assessed at baseline. For individuals with normal levels of SPG1, measurement of anti-CagA antibodies may provide better discrimination of gastric cancer risk.
The current Cox regression analysis associated low SPG1 with gastric cancer risk, in line with our previous nested case-control analysis of cases diagnosed through April 2006. 38 We found a stronger association within shorter time intervals with the highest HR observed for cancers occurring within 5 years after baseline (Table S1 ). Our findings replicate previous studies (Table S4) , not only regarding the significant association of low SPG1 with gastric cancer overall, but also higher risk estimates for noncardia subsites and intestinal-type histology.
The major strength of our study is the use of prediagnostic samples analysed for SPG1 and anti-H. pylori seropositivity at baseline, with a long follow-up period. Another strength is that we have the largest number of cases (n = 329) ever studied in a Western population, allowing us for a more comprehensive analysis across group categories and anatomical and histological subtypes, as well as accounting for potential confounder effects. While this study has a large number of gastric cancer cases, sub-group analyses are likely to be underpowered.
Although both men (as compared to women) and smokers (as compared to nonsmokers) have higher risks of gastric cancer, our findings based on male smokers may have limited generalizability.
Nonetheless, the risk estimates were similar to the previous studies.
Another possible limitation of our study is that the SPG1 measurement selected high-risk individuals for further screening with 100.00 P heterogeneity = .22 P heterogeneity = .62 F I G U R E 1 Association of pre-diagnostic and 3-year follow-up measurement of serum pepsinogen 1 and subsequent gastric cancer risk in the ATBC Study. ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention, f/u, follow-up, OR, odds ratio, CI, confidence interval, SPG1, Serum pepsinogen 1. Group A: H. pylori (À) and normal SPG1, Group B: H. pylori (+) and normal SPG1, Group C: H. pylori (+) and low SPG1, Group D: H. pylori (À) and low SPG1. Model adjusted for age at randomization, type of intervention, pack years of smoking, alcohol drinking, education, fruit intake, vegetable intake. *Numbers in parentheses indicate gastric cancer cases in each group at follow-up. Cases diagnosed before follow-up measurements (≤3 years) were excluded from the analysis (n = 5) endoscopy, but we did not find evidence of excess cancer diagnoses among the screened fraction of the cohort compared to those who were unscreened. Moreover, the analysis incorporating H. pylori serology information was based on availability of data from prior nested case-control datasets for various cancers, but the results were unchanged by restriction to the matched gastric cancer casecontrol set. We also did not gather information about possible H. pylori eradication therapy post-enrollment.
In conclusion, we found that the joint consideration of SPG1 and anti-H. pylori whole cell and CagA seropositivity is a potentially useful predictor for the development of gastric cancer, especially noncardia gastric cancer, in a large population study of a Western population. This noninvasive and relatively inexpensive method could be used to identify high risk individuals for definitive evaluation by endoscopy and/or to advise on H. pylori eradication. Risk stratification could potentially be improved by incorporating other factors, such as an individual's genetic and epigenetic information. 66 Further studies of cost-effectiveness and of risk-specific screening intervals are warranted for development of personalized screening guidelines.
